List of Antisense Oligonucleotides Companies in United Kingdom - 3

Nanovery is a biotechnology company founded in 2018 and based in Newcastle Helix, UK. The company specializes in nucleic acid nanorobotics, focusing on developing liquid nanorobot technology to advance nucleic acid research, particularly in RNA therapeutic analysis and biomarker quantification. Nanovery operates in the biotechnology sector, emphasizing research and development. The company's main offering is a proprietary platform that utilizes DNA nanorobotic sensors to quantify nucleic acid sequences in liquid samples. This platform simplifies the testing process by adding nanorobots to samples and measuring fluorescence to determine nucleic acid concentrations. Nanovery's technology supports RNA therapeutic development, biomarker analysis, and disease diagnostics, including early-stage detection. The integration of AI enhances data analysis and scalability, making the technology suitable for complex media. Nanovery has raised a total of $2.92 million in funding, with notable investors including Northstar Ventures and Innovate UK. The company aims to streamline testing protocols in biotech research, focusing on speed, cost-efficiency, and accuracy.

SENISCA is a biotech spinout company from the University of Exeter, founded in 2020 and dedicated to the development of new approaches to reverse cellular senescence (senotherapeutics). Our founders are world leaders in molecular and cellular biology and have patent-protected an innovation for the reversal of cellular senescence. This innovation works by restoring the ability of cells to ‘fine tune’ the expression of their genes to rejuvenate aged cells. At SENISCA, we are using this knowledge, concerning how and why cells become senescent, to develop a new generation of oligonucleotide-based interventions, to turn back the ageing clock in old cells and to target the diseases and aesthetic signs of ageing.

SynaptixBio is a rare disease biotech company that is pioneering ground-breaking treatments for severe leukodystrophies and other childhood neurodegenerative diseases.    SynaptixBio's mission is to deliver gene therapies for fatal leukodystrophies in children caused by loss of function or mutation in a single gene. Using a breadth of platforms including antisense oligonucleotide (ASO)-based technology, we can silence the expression of the toxic gene to reverse disease progression. This approach will create life saving treatments for severe genetic diseases that affect the central nervous system.